A joint resolution introduced by Assembly Members Eric Houghtaling and Joann Downey to designate the Monday before Thanksgiving as "A Day in the Life - Type 1 Diabetes Day" was approved Monday, October 29.
The joint resolution (AJR152) asks the Governor to annually issue a proclamation recognizing the Monday before Thanksgiving Day as "A Day in the Life - Type 1 Diabetes Day," and calling upon public officials and the citizens of New Jersey to observe the month with appropriate activities and programs.
“Diabetes impacts a significant proportion of New Jersey’s population, with approximately 11 percent of our adult population diagnosed, according to the American Diabetes Association,” said Assemblyman Eric Houghtaling. “With so many of our residents impacted by this disease, it is important that we do our part to raise awareness of Type 1 diabetes and establish a supportive community upon which New Jerseyans living with diabetes can rely.”
“In an increasingly divisive world, we are proud to support a holiday that underscores the importance of inclusion, understanding and compassion,” said Assemblywoman Joann Downey. “We are asking the residents of New Jersey to walk a mile in the shoes of a neighbor living with Type 1 diabetes in order to gain a deeper understanding into the challenges they face on a daily basis. At the same time, we are shining a spotlight on those who live with this disease, and encourage the community to learn more about the individual as a whole, rather than define them by their disease.”
As many as three million Americans have T1D, including 40,000 in New Jersey. Each year more than 30,000 children and adults, or approximately 80 people every day, are diagnosed with T1D, resulting in approximately $14.9 billion in healthcare costs each year.
The Assembly Members worked closely with JDRF to draft this important resolution. JDRF is the leading global organization funding T1D research. Their mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.2 billion in research funding since its inception. JDRF is an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. JDRF collaborates with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Its staff and volunteers are dedicated to advocacy, community engagement and our vision of a world without T1D.